| Texto completo | |
| Autor(es): Mostrar menos - |
Picanco-Castro, Virginia
;
Moco, Pablo Diego
;
Mizukami, Amanda
;
Vaz, Leticia Delfini
;
Fernandes Pereira, Marcelo de Souza
;
Silvestre, Renata Nacasaki
;
Cottas de Azevedo, Julia Teixeira
;
Bomfim, Aline de Sousa
;
de Abreu Neto, Mario Soares
;
Ribeiro Malmegrim, Kelen Cristina
;
Swiech, Kamilla
;
Covas, Dimas Tadeu
Número total de Autores: 12
|
| Tipo de documento: | Artigo Científico |
| Fonte: | Hematology, Transfusion and Cell Therapy; v. 42, n. 2, p. 9-pg., 2020-04-01. |
| Resumo | |
Introduction: Adoptive transfer of T cells expressing a CD19-specific chimeric antigen receptor (CAR) has shown impressive response rates for the treatment of CD19 + B-cell malignancies in numerous clinical trials. The CAR molecule, which recognizes cell-surface tumor-associated antigen independently of human leukocyte antigen (HLA), is composed by one or more signaling molecules to activate genetically modified T cells for killing, proliferation, and cytokine production. Objectives: In order to make this treatment available for a larger number of patients, we developed a simple and efficient platform to generate and expand CAR-T cells. Methods: Our approach is based on a lentiviral vector composed by a second-generation CAR that signals through a 41BB and CD3-zeta endodomain. Conclusions: In this work, we show a high-level production of the lentiviral vector, which was successfully used to generate CAR-T cells. The CAR-T cells produced were highly cytotoxic and specific against CD19+ cells in vitro and in vivo, being able to fully control disease progression in a xenograft B-cell lymphoma mouse model. Our work demonstrates the feasibility of producing CAR-T cells in an academic context and can serve as a paradigm for similar institutions. Nevertheless, the results presented may contribute favoring the translation of the research to the clinical practice. (C) 2019 Associacao Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Editora Ltda. (AU) | |
| Processo FAPESP: | 12/23228-4 - Expansão in vitro de células estromais mesenquimais e caracterização do secretoma: aplicações terapêuticas e biotecnológicas |
| Beneficiário: | Amanda Mizukami Martins |
| Modalidade de apoio: | Bolsas no Brasil - Doutorado |
| Processo FAPESP: | 17/09491-8 - Modelos murinos de Leucemia/Linfoma Linfoides para avaliar os efeitos antitumorais de células T modificadas com CAR-CD19 |
| Beneficiário: | Marcelo de Souza Fernandes Pereira |
| Modalidade de apoio: | Bolsas no Brasil - Pós-Doutorado |
| Processo FAPESP: | 16/08374-5 - Modificação de linfócitos T com receptor de antígenos quimérico anti-CD19 |
| Beneficiário: | Pablo Diego Moço |
| Modalidade de apoio: | Bolsas no Brasil - Mestrado |
| Processo FAPESP: | 13/08135-2 - CTC - Centro de Terapia Celular |
| Beneficiário: | Dimas Tadeu Covas |
| Modalidade de apoio: | Auxílio à Pesquisa - Centros de Pesquisa, Inovação e Difusão - CEPIDs |